Pathophysiology of a sickle cell trait mouse model:: Human αβS transgenes with one mouse β-globin allele

被引:19
作者
Noguchi, CT [1 ]
Gladwin, M
Diwan, B
Merciris, P
Smith, R
Yu, XB
Buzard, G
Fitzhugh, A
Keefer, LK
Schechter, AN
Mohandas, N
机构
[1] NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA
[2] NIH, Dept Crit Care Med, CC, Bethesda, MD 20892 USA
[3] NCI, Intramural Res Support Program, SAIC, Frederick, MD 21702 USA
[4] NCI, Comparat Carcinogenesis Lab, Frederick, MD 21702 USA
[5] Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA
关键词
sickle cell trait; pathophysiology; transgenic mouse; kidney pathology; oxygen affinity;
D O I
10.1006/bcmd.2001.0469
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As a potential model for sickle cell trait (AS), we examined mice containing one normal mouse beta-globin allele in combination with a human hemoglobin S (halphabeta(S)) transgene (mbeta/hS). The mice segregated into two subpopulations containing low and high proportions of hemoglobin S (mbeta/hS1 and mbeta/hS2, respectively) that was associated with one or two human halphabeta(S) transgenes. We noted striking kidney pathology (cortical cysts, hyperplastic tubules, and glomerulonephritis), increasing with age and with greater severity in mbeta/hS1. mbeta/hS2 animals were largely tolerant to 5% O-2 for 1 h, whereas 80% of mbeta/hS1 mice died, exhibiting acute sequestration of erythrocytes in spleen, liver, and heart. These pathologies appear to result from a decreased oxygen affinity of the hybrid (human alpha/mouse beta) hemoglobins with a mild beta-thalassemia phenotype. Thus, these mouse models of sickle trait seem to manifest their renal pathology and sensitivity to hypoxia by mechanisms related to low tissue oxygen delivery and are different from the human syndrome. Analyses of parameters such as P-50, red cell indices, and genetic background are necessary in establishing potential relevance of any mouse model of the sickle cell syndromes.
引用
收藏
页码:971 / 977
页数:7
相关论文
共 26 条
[1]  
[Anonymous], 1992, Sickle cell disease
[2]  
Ataga KI, 2000, AM J HEMATOL, V63, P205, DOI 10.1002/(SICI)1096-8652(200004)63:4<205::AID-AJH8>3.0.CO
[3]  
2-8
[4]  
Bissé E, 1998, CLIN CHEM, V44, P2172
[5]   Genetic correction of sickle cell disease: Insights using transgenic mouse models [J].
Blouin, MJ ;
Beauchemin, H ;
Wright, A ;
De Paepe, M ;
Sorette, M ;
Bleau, AM ;
Nakamoto, B ;
Ou, CN ;
Stamatoyannopoulos, G ;
Trudel, M .
NATURE MEDICINE, 2000, 6 (02) :177-182
[6]  
BRITTENHAM GM, 1985, BLOOD, V65, P183
[7]   Mechanisms of disease - Pathogenesis and treatment of sickle cell disease [J].
Bunn, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :762-769
[8]   RENAL MEDULLARY CARCINOMA - THE 7TH SICKLE-CELL NEPHROPATHY [J].
DAVIS, CJ ;
MOSTOFI, FK ;
SESTERHENN, IA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (01) :1-11
[9]   Second generation knockout sickle mice: the effect of HbF [J].
Fabry, ME ;
Suzuka, SM ;
Weinberg, RS ;
Lawrence, C ;
Factor, SM ;
Gilman, JG ;
Costantini, F ;
Nagel, RL .
BLOOD, 2001, 97 (02) :410-418
[10]   Splenic syndrome in sickle cell trait: Four case presentations and a review of the literature [J].
Franklin, QJ ;
Compeggie, M .
MILITARY MEDICINE, 1999, 164 (03) :230-233